製品番号: HY-W565665

(S)-HPMPA

Name: (S)-HPMPA
Brand: MedChemExpress
SKU: HY-W565665
Price: 136.00 USD
Availability: InStock
Rating: 5 (1 reviews)

カスタマーレビュー

Based on 1 Customer Validation

(S)-HPMPA is an antiviral agent. (S)-HPMPA can bind to and interfere with viral DNA polymerase activity, thereby inhibiting viral DNA synthesis. (S)-HPMPA can be used for the study of DNA viruses.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度 : 99.89%
CAS 番号: 92999-29-6
分子式: C₉H₁₄N₅O₅P
分子量:303.21

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

(S)-HPMPA 構造式

CAS 番号: 92999-29-6

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
化学情報
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

DNA Polymerase

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
BSC-1	CC₅₀	89.3 μM Compound: HPMPA	Cytotoxicity against african green monkey BSC1 cells Cytotoxicity against african green monkey BSC1 cells	[PMID: 17420214]
BSC-1	EC₅₀	10.2 μM Compound: HPMPA	Antiviral activity against Simian virus 40 PML2 DAR in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Simian virus 40 PML2 DAR in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17420214]
BSC-1	EC₅₀	12.3 μM Compound: HPMPA	Antiviral activity against Simian virus 40 A2895 in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Simian virus 40 A2895 in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17420214]
BSC-1	EC₅₀	15.4 μM Compound: HPMPA	Antiviral activity against Simian virus 40 PML1 EK in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Simian virus 40 PML1 EK in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17420214]
HEL	EC₅₀	0.036 μM Compound: HPMPA	Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.08 μM Compound: HPMPA	Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.081 μg/mL Compound: (S)-HPMPA	Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	0.11 μg/mL Compound: (S)-HPMPA	Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	0.12 μM Compound: HPMPA	Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.17 μM Compound: HPMPA	Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.2 μM Compound: HPMPA	Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.91 μg/mL Compound: (S)-HPMPA	Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	1.2 μg/mL Compound: (S)-HPMPA	Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	1.9 μM Compound: HPMPA	Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	2 μg/mL Compound: (S)-HPMPA	Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	2.1 μM Compound: HPMPA	Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	2.3 μg/mL Compound: (S)-HPMPA	Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	3.3 μg/mL Compound: (S)-HPMPA	Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	6.2 μg/mL Compound: (S)-HPMPA	Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL 299	CC₅₀	32 μM Compound: 1b, HPMPA	Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis	[PMID: 17893157]
HEL 299	EC₅₀	0.5 μM Compound: 1b, HPMPA	Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	[PMID: 17893157]
HepG2 2.2.15	CC₅₀	>300 μM Compound: (S)-HPMPA	Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red assay Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red assay	[PMID: 19398648]
HepG2 2.2.15	EC₅₀	1.2 μM Compound: (S)-HPMPA	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as decrease in extracellular viral DNA level after 24 hrs by blot hybridization assay Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as decrease in extracellular viral DNA level after 24 hrs by blot hybridization assay	[PMID: 19398648]
HFF	CC₅₀	>289 μM Compound: (S)-HPMPA	Cytotoxicity against HFF cell Cytotoxicity against HFF cell	[PMID: 16539388]
HFF	CC₅₀	>289 μM Compound: (S)-HPMPA	Cytotoxicity against HFF cells after 7 days Cytotoxicity against HFF cells after 7 days	[PMID: 17846137]
HFF	EC₅₀	2.7 μM Compound: (S)-HPMPA	Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells	[PMID: 16539388]
HFF	EC₅₀	2.7 μM Compound: (S)-HPMPA	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	4 μM Compound: (S)-HPMPA	Antiviral activity against Cowpox virus Brighton replication in HFF cells Antiviral activity against Cowpox virus Brighton replication in HFF cells	[PMID: 16539388]
HFF	EC₅₀	4 μM Compound: (S)-HPMPA	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	6.5 μM Compound: (S)-HPMPA	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	IC₅₀	0.41 μM Compound: 1, (S)-HPMPA	Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay	[PMID: 21812420]
HFF	IC₅₀	100 μM Compound: 1, (S)-HPMPA	Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay	[PMID: 21812420]
HFF	IC₅₀	2 μM Compound: 1, (S)-HPMPA	Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay	[PMID: 21812420]
HFF	IC₅₀	35 μM Compound: 1, (S)-HPMPA	Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay	[PMID: 21812420]
HFF	IC₅₀	4 μM Compound: 1, (S)-HPMPA	Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay	[PMID: 21812420]
Huh-7	CC₅₀	>100 μM Compound: (S)-HPMPA	Cytotoxicity against human Huh7.5 cells administered for 3 days measured 24 hrs after last dose by neutral red dye uptake assay Cytotoxicity against human Huh7.5 cells administered for 3 days measured 24 hrs after last dose by neutral red dye uptake assay	[PMID: 19289518]
Huh-7	EC₅₀	>100 μM Compound: (S)-HPMPA	Antiviral activity against HCV1B BM4-5 infected in human Huh7.5 cells assessed as decrease in intracellular viral RNA treated for 3 days measured 24 hrs after last dose by luciferase reporter gene-based blot hybridization Antiviral activity against HCV1B BM4-5 infected in human Huh7.5 cells assessed as decrease in intracellular viral RNA treated for 3 days measured 24 hrs after last dose by luciferase reporter gene-based blot hybridization	[PMID: 19289518]
KB	IC₅₀	>100 μM Compound: 1, (S)-HPMPA	Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis	[PMID: 21812420]

体外実験

(S)-HPMPApp is a good substrate for vaccinia DNA polymerase, readily incorporating into the DNA strand without causing strand termination; instead, it exerts its inhibitory effect by inhibiting 3'-to-5' exonuclease activity and blocking template strand elongation^[1].
(S)-HPMPA (1-100 μg/mL, 24-72 h) can effectively inhibit viral replication in primary rabbit kidney cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

化学情報

CAS 番号 92999-29-6
性状 Solid
分子量 303.21
分子式 C₉H₁₄N₅O₅P
Color White to off-white
SMILES

O=P(O)(O)CO[C@H](CO)CN1C2=NC=NC(N)=C2N=C1
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

H₂O : 62.5 mg/mL (206.13 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2980 mL

16.4902 mL

32.9804 mL

5 mM

0.6596 mL

3.2980 mL

6.5961 mL

10 mM

0.3298 mL

1.6490 mL

3.2980 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (272 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res. 2009 May;82(2):A84-98. [Content Brief]

[2]. De Clercq E, et al. A novel selective broad-spectrum anti-DNA virus agent. Nature. 1986 Oct 2-8;323(6087):464-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	3.2980 mL	16.4902 mL	32.9804 mL	82.4511 mL
	5 mM	0.6596 mL	3.2980 mL	6.5961 mL	16.4902 mL
	10 mM	0.3298 mL	1.6490 mL	3.2980 mL	8.2451 mL
	15 mM	0.2199 mL	1.0993 mL	2.1987 mL	5.4967 mL
	20 mM	0.1649 mL	0.8245 mL	1.6490 mL	4.1226 mL
	25 mM	0.1319 mL	0.6596 mL	1.3192 mL	3.2980 mL
	30 mM	0.1099 mL	0.5497 mL	1.0993 mL	2.7484 mL
	40 mM	0.0825 mL	0.4123 mL	0.8245 mL	2.0613 mL
	50 mM	0.0660 mL	0.3298 mL	0.6596 mL	1.6490 mL
	60 mM	0.0550 mL	0.2748 mL	0.5497 mL	1.3742 mL
	80 mM	0.0412 mL	0.2061 mL	0.4123 mL	1.0306 mL
	100 mM	0.0330 mL	0.1649 mL	0.3298 mL	0.8245 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

(S)-HPMPA

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示

生物活性

製品説明

IC₅₀ & Target

Cellular Effect

体外実験

化学情報

溶剤 & 溶解度

体外:

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Keywords

最近チェックした製品

(S)-HPMPA

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示

生物活性

製品説明

IC50 & Target

Cellular Effect

体外実験

化学情報

溶剤 & 溶解度

体外:

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

(S)-HPMPA 関連分類

HY-W565665 関連分類

Bioz

Keywords

最近チェックした製品

IC₅₀ & Target